Pilon M, Hindi J, St-Jean I, Jutras M, Brouillette M, Mongrain I
Eur J Clin Pharmacol. 2024; 81(2):321-332.
PMID: 39704823
DOI: 10.1007/s00228-024-03786-3.
Sethi R, Vishwakarma P, Pradhan A
Card Fail Rev. 2024; 10:e15.
PMID: 39588014
PMC: 11588114.
DOI: 10.15420/cfr.2024.10.
Halaseh R, Sauer A, Vardeny O, Canonico M, Harrington J, Svetlichnaya J
Heart Fail Rev. 2024; 30(2):287-291.
PMID: 39476221
DOI: 10.1007/s10741-024-10462-2.
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M
Kidney Int Rep. 2024; 9(10):3035-3044.
PMID: 39430198
PMC: 11489825.
DOI: 10.1016/j.ekir.2024.07.009.
Kurgansky K, Parker R, Djousse L, Gagnon D, Joseph J
J Am Heart Assoc. 2024; 13(14):e032231.
PMID: 38979805
PMC: 11292773.
DOI: 10.1161/JAHA.123.032231.
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.
Balestrieri G, Limonta R, Ponti E, Merlo A, Sciatti E, DIsa S
Card Fail Rev. 2024; 10:e05.
PMID: 38708376
PMC: 11066852.
DOI: 10.15420/cfr.2023.13.
[Heart Failure With Preserved Ejection Fraction: A Problem Of Contemporary Cardiology].
Saldarriaga-Giraldo C, Ramirez-Ramos C, Gallego C, Castilla-Agudelo G, Aranzazu-Uribe M, Saldarriaga-Betancur S
Arch Peru Cardiol Cir Cardiovasc. 2024; 1(2):85-93.
PMID: 38572331
PMC: 10986356.
DOI: 10.47487/apcyccv.v1i2.53.
Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines.
MacDonald B, Virani S, Zieroth S, Turgeon R
CJC Open. 2023; 5(8):629-640.
PMID: 37720183
PMC: 10502425.
DOI: 10.1016/j.cjco.2023.05.008.
Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials.
Kresoja K, Unterhuber M, Wachter R, Rommel K, Besler C, Shah S
EBioMedicine. 2023; 96:104795.
PMID: 37689023
PMC: 10498181.
DOI: 10.1016/j.ebiom.2023.104795.
Endotrophin, a Collagen VI Formation-Derived Peptide, in Heart Failure.
Chirinos J, Zhao L, Reese-Petersen A, Cohen J, Genovese F, Richards A
NEJM Evid. 2023; 1(10).
PMID: 37645406
PMC: 10465122.
DOI: 10.1056/evidoa2200091.
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Kim M, Prasad M, Burton Y, Kolseth C, Zhao Y, Chandrashekar P
J Am Heart Assoc. 2023; 12(15):e029705.
PMID: 37522238
PMC: 10492973.
DOI: 10.1161/JAHA.123.029705.
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.
Kintscher U, Edelmann F
Cardiovasc Diabetol. 2023; 22(1):162.
PMID: 37386461
PMC: 10311906.
DOI: 10.1186/s12933-023-01899-0.
Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Testani J
J Card Fail. 2023; 30(2):340-346.
PMID: 37301248
PMC: 10947725.
DOI: 10.1016/j.cardfail.2023.05.018.
The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A
Med Arch. 2023; 77(2):105-111.
PMID: 37260796
PMC: 10227849.
DOI: 10.5455/medarh.2023.77.105-111.
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.
Youn J, Kim D, Cho J, Cho D, Park S, Jung M
Int J Heart Fail. 2023; 5(2):66-81.
PMID: 37180564
PMC: 10172080.
DOI: 10.36628/ijhf.2023.0011.
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.
Youn J, Kim D, Cho J, Cho D, Park S, Jung M
Korean Circ J. 2023; 53(4):217-238.
PMID: 37161681
PMC: 10172201.
DOI: 10.4070/kcj.2023.0047.
Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial.
Saksena S, Slee A, Natale A, Lakkireddy D, Shah D, Di Biase L
Europace. 2023; 25(5).
PMID: 37078691
PMC: 10228603.
DOI: 10.1093/europace/euad095.
Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial.
Brandt-Jacobsen N, Johansen M, Rasmussen J, Dalsgaard M, Kumler T, Faber J
BMC Cardiovasc Disord. 2023; 23(1):175.
PMID: 37003987
PMC: 10064675.
DOI: 10.1186/s12872-023-03183-1.
Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research.
Mamazhakypov A, Lother A
Front Cardiovasc Med. 2023; 10:1118516.
PMID: 36793473
PMC: 9922727.
DOI: 10.3389/fcvm.2023.1118516.
New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.
Parra-Lucares A, Romero-Hernandez E, Villa E, Weitz-Munoz S, Vizcarra G, Reyes M
Biomedicines. 2023; 11(1).
PMID: 36672578
PMC: 9856156.
DOI: 10.3390/biomedicines11010070.
